Back To Schedule
Tuesday, March 15 • 1:15pm - 2:00pm
Panel: Exploring Innovative and Alternative Deal Structures to Mitigate Risk

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

  • How do you decide what the “right” deal structure is for the collaboration?
  • Building flexibility into the deal structure
  • Managing uncertainty: Different structures, goals and valuations for early vs. late stage deals
  • Deciding whether to go the M&A route vs. alliances or product acquisition
  • Going beyond the conventional: Examples of innovative deal structures: joint ventures, subsidiary programs, non-equity structures, royalty financing and more

avatar for Mark Stead

Mark Stead

Senior Director in Business Development, Exelixis
Mark Stead, Ph.D. is Senior Business Development Director at Exelixis, Inc. In this role, he is responsible for the negotiation of partnerships and strategic transactions in support of Exelixis’ mission to accelerate the discovery, development and commercialization of... Read More →

avatar for Scott Saywell

Scott Saywell

Chief Business Officer, Herophilus
Scott Saywell is the Chief Business Officer at Herophilus, a San Francisco-based neurotherapeutics company focused on curing brain diseases with its proprietary technology platform based on in vitro human tissue models.  Scott has over twenty-five years of experience in the biotech... Read More →
avatar for Karen Martell

Karen Martell

Transaction Lead - Biologics Discovery California, Bristol-Myers Squibb
Karen has over twenty-five years of business development, venture investment and scientific experience in the biopharma industry. She is based at the Redwood City, California site of Bristol-Myers Squibb where she structures, negotiates, and executes transactions with discovery-stage... Read More →

Tuesday March 15, 2022 1:15pm - 2:00pm PDT